American Century Companies Inc. Has $56.11 Million Stake in Insmed Incorporated (NASDAQ:INSM)

American Century Companies Inc. grew its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 12.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 812,780 shares of the biopharmaceutical company’s stock after purchasing an additional 89,097 shares during the period. American Century Companies Inc. owned about 0.45% of Insmed worth $56,114,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Jennison Associates LLC boosted its stake in shares of Insmed by 0.6% in the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock valued at $53,424,000 after buying an additional 4,560 shares during the period. Capital CS Group LLC bought a new stake in shares of Insmed during the 4th quarter valued at $586,000. Orion Portfolio Solutions LLC grew its holdings in shares of Insmed by 48.5% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock worth $2,050,000 after purchasing an additional 9,170 shares in the last quarter. Ally Bridge Group NY LLC increased its position in shares of Insmed by 16.9% in the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after purchasing an additional 21,833 shares during the period. Finally, Vestal Point Capital LP raised its stake in Insmed by 113.3% in the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after purchasing an additional 850,000 shares in the last quarter.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of analyst reports. Wells Fargo & Company increased their price objective on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Stifel Nicolaus decreased their price objective on shares of Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Royal Bank of Canada restated an “outperform” rating and set a $100.00 target price on shares of Insmed in a research note on Wednesday, March 19th. UBS Group lifted their price target on Insmed from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Finally, Bank of America upped their price objective on Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $94.00.

Insmed Trading Down 2.5 %

Shares of NASDAQ INSM opened at $76.57 on Thursday. The firm has a 50 day moving average price of $77.97 and a two-hundred day moving average price of $73.91. The stock has a market cap of $13.86 billion, a P/E ratio of -13.70 and a beta of 1.28. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. As a group, equities analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $77.03, for a total transaction of $1,444,312.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at approximately $25,742,347.58. This trade represents a 5.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Martina M.D. Flammer sold 3,344 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total value of $220,403.04. Following the completion of the transaction, the insider now directly owns 102,766 shares in the company, valued at $6,773,307.06. This represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock valued at $42,992,528 over the last ninety days. 4.60% of the stock is owned by company insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.